The project aims to accelerate the development of clinical cancer diagnostic solutions for acute myeloid leukemia (AML) and bladder cancer. Following successful progress and review within the agreed project timeline, the next installment is now approved for disbursement.
 
Over the course of the three-year project, Qlucore will develop and launch CE-marked software for clinical cancer diagnostics in AML and bladder cancer. The solutions are intended for use in clinical laboratories and will also support the development of companion diagnostics in collaboration with pharmaceutical partners.
 
 
“This EU payment strengthens Qlucore financially and supports our continued progress in RNA-seq-based clinical diagnostics,” says Carl-Johan Ivarsson, CEO of Qlucore.
 
The initial target market includes clinical laboratories across Europe, followed by expansion into the US market.